- The European Medicines Agency (EMA) has authorized a third dose of Moderna Inc's MRNA COVID-19 vaccine for immunocompromised people.
- Related Link: After Pfizer, Now Moderna Touts Data Supporting COVID-19 Booster Dose.
- The approval comes for the booster given at least 28 days after the second dose to severely immunocompromised individuals 12 years of age or older.
- Related: Moderna Shares Linger At 2-Month Lows: What's Next For The COVID-19 Vaccine Company.
- Price Action: MRNA stock is up 2.07% at $332.49 during the market session on the last check Tuesday.
- Image by Spencer Davis from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
